請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/6120
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李宗璘(Tsung-Lin Li) | |
dc.contributor.author | Yu-Chen Liu | en |
dc.contributor.author | 劉祐禎 | zh_TW |
dc.date.accessioned | 2021-05-16T16:21:20Z | - |
dc.date.available | 2018-08-08 | |
dc.date.available | 2021-05-16T16:21:20Z | - |
dc.date.copyright | 2013-08-08 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-07-30 | |
dc.identifier.citation | References
1. Fischbach, M.A. & Walsh, C.T. Antibiotics for Emerging Pathogens. Science 325, 1089-1093 (2009). 2. Silver, L.L. Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 6, 41-55 (2007). 3. Payne, D.J., Gwynn, M.N., Holmes, D.J. & Pompliano, D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6, 29-40 (2007). 4. Louis B, R. Antimicrobial resistance in gram-positive bacteria. Am. J. Infect. Control 34, S11-S19 (2006). 5. Murray, B.E. Vancomycin-Resistant Enterococcal Infections. New Engl. J. Med. 342, 710-721 (2000). 6. Chan, P.F., Holmes, D.J. & Payne, D.J. Finding the gems using genomic discovery: antibacterial drug discovery strategies – the successes and the challenges. Drug Discovery Today: Therapeutic Strategies 1, 519-527 (2004). 7. Khare, M. & Keady, D. Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection. Expert Opin Pharmacother 4, 165-177 (2003). 8. Marsden, A.F.A. et al. Engineering Broader Specificity into an Antibiotic-Producing Polyketide Synthase. Science 279, 199-202 (1998). 9. Li, Y.-S. et al. A Unique Flavin Mononucleotide-Linked Primary Alcohol Oxidase for Glycopeptide A40926 Maturation. J. Am. Chem. Soc. 129, 13384-13385 (2007). 10. Ho, J.-Y. et al. Glycopeptide Biosynthesis: Dbv21/Orf2* from dbv/tcp Gene Clusters Are N-Ac-Glm Teicoplanin Pseudoaglycone Deacetylases and Orf15 from cep Gene Cluster Is a Glc-1-P Thymidyltransferase. J. Am. Chem. Soc. 128, 13694-13695 (2006). 11. Leskovac, V., Trivic, S., Wohlfahrt, G., Kandrac, J. & Pericin, D. Glucose oxidase from Aspergillus niger: the mechanism of action with molecular oxygen, quinones, and one-electron acceptors. Int. J. Biochem. Cell Biol. 37, 731-750 (2005). 12. Snook, C.F., Tipton, P.A. & Beamer, L.J. Crystal Structure of GDP-Mannose Dehydrogenase: A Key Enzyme of Alginate Biosynthesis in P. aeruginosa†,‡. Biochemistry (Mosc). 42, 4658-4668 (2003). 13. Campbell, R.E., Mosimann, S.C., van de Rijn, I., Tanner, M.E. & Strynadka, N.C.J. The First Structure of UDP-Glucose Dehydrogenase Reveals the Catalytic Residues Necessary for the Two-fold Oxidation†,‡. Biochemistry (Mosc). 39, 7012-7023 (2000). 14. Chan, H.-C. et al. Regioselective deacetylation based on teicoplanin-complexed Orf2* crystal structures. Molecular BioSystems 7, 1224-1231 (2011). 15. Li, T.-L. et al. Biosynthetic Gene Cluster of the Glycopeptide Antibiotic Teicoplanin: Characterization of Two Glycosyltransferases and the Key Acyltransferase. Chem. Biol. 11, 107-119 (2004). 16. Alexeev, I., Sultana, A., Mantsala, P., Niemi, J. & Schneider, G. Aclacinomycin oxidoreductase (AknOx) from the biosynthetic pathway of the antibiotic aclacinomycin is an unusual flavoenzyme with a dual active site. Proc. Natl. Acad. Sci. USA 104, 6170-6175 (2007). 17. Huang, C.-H. et al. Crystal Structure of Glucooligosaccharide Oxidase from Acremonium strictum: A NOVEL FLAVINYLATION OF 6-S-CYSTEINYL, 8α-N1-HISTIDYL FAD. J. Biol. Chem. 280, 38831-38838 (2005). 18. Whittaker, J.W. Free Radical Catalysis by Galactose Oxidase. Chem. Rev. 103, 2347-2364 (2003). 19. Dym, O. & Eisenberg, D. Sequence-structure analysis of FAD-containing proteins. Protein Sci. 10, 1712-1728 (2001). 20. Otwinowski, Z. & Minor, W. [20] Processing of X-ray diffraction data collected in oscillation mode, in Methods in Enzymology, Vol. Volume 276. (ed. Charles W. Carter, Jr.) 307-326 (Academic Press, 1997). 21. Kantardjieff, K.A. & Rupp, B. Matthews coefficient probabilities: Improved estimates for unit cell contents of proteins, DNA, and protein–nucleic acid complex crystals. Protein Sci. 12, 1865-1871 (2003). 22. Vagin, A. & Teplyakov, A. MOLREP: an Automated Program for Molecular Replacement. J. Appl. Crystallogr. 30, 1022-1025 (1997). 23. McRee, D.E. XtalView/Xfit—A Versatile Program for Manipulating Atomic Coordinates and Electron Density. J. Struct. Biol. 125, 156-165 (1999). 24. Brunger, A.T. et al. Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination. Acta Crystallographica Section D 54, 905-921 (1998). 25. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of Macromolecular Structures by the Maximum-Likelihood Method. Acta Crystallographica Section D 53, 240-255 (1997). 26. Schuck, P. Size-Distribution Analysis of Macromolecules by Sedimentation Velocity Ultracentrifugation and Lamm Equation Modeling. Biophys. J. 78, 1606-1619 (2000). 27. Borch, R.F., Bernstein, M.D. & Durst, H.D. Cyanohydridoborate anion as a selective reducing agent. J. Am. Chem. Soc. 93, 2897-2904 (1971). 28. Winkler, A. et al. A concerted mechanism for berberine bridge enzyme. Nat. Chem. Biol. 4, 739-741 (2008). 29. Koteva, K. et al. A vancomycin photoprobe identifies the histidine kinase VanSsc as a vancomycin receptor. Nat Chem Biol 6, 327-329 (2010). 30. Higgins, D.L. et al. Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 1127-1134 (2005). 31. Roecker, A.M. & Pope, S.D. Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections. Expert Opinion on Pharmacotherapy 9, 1745-1754 (2008). 32. Linden, P.K. Vancomycin resistance: are there better glycopeptides coming? Expert review of anti-infective therapy 6, 917-928 (2008). 33. Bailey, J. & Summers, K.M. Dalbavancin: a new lipoglycopeptide antibiotic. Am. J. Health. Syst. Pharm. 65, 599-610 (2008). 34. Kim, A., Kuti, J.L. & Nicolau, D.P. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert opinion on investigational drugs 16, 717-733 (2007). References 1. Singh, M.P. et al. Mannopeptimycins, New Cyclic Glycopeptide Antibiotics Produced by Streptomyces hygroscopicus LL-AC98: Antibacterial and Mechanistic Activities. Antimicrob. Agents Chemother. 47, 62-69 (2003). 2. He, H. et al. Mannopeptimycins, Novel Antibacterial Glycopeptides from Streptomyces hygroscopicus, LL-AC98. J. Am. Chem. Soc. 124, 9729-9736 (2002). 3. Breukink, E. & de Kruijff, B. Lipid II as a target for antibiotics. Nat Rev Drug Discov 5, 321-323 (2006). 4. Koehn, F.E. New Strategies and Methods in the Discovery of Natural Product Anti-Infective Agents: The Mannopeptimycins. J. Med. Chem. 51, 2613-2617 (2008). 5. Malabarba, A. & Goldstein, B.P. Origin, structure, and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother. 55 Suppl 2, ii15-20 (2005). 6. Van Bambeke, F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr Opin Pharmacol 4, 471-478 (2004). 7. Ruzin, A. et al. Mechanism of Action of the Mannopeptimycins, a Novel Class of Glycopeptide Antibiotics Active against Vancomycin-Resistant Gram-Positive Bacteria. Antimicrob. Agents Chemother. 48, 728-738 (2004). 8. Petersen, P.J., Wang, T.Z., Dushin, R.G. & Bradford, P.A. Comparative In Vitro Activities of AC98-6446, a Novel Semisynthetic Glycopeptide Derivative of the Natural Product Mannopeptimycin α, and Other Antimicrobial Agents against Gram-Positive Clinical Isolates. Antimicrob. Agents Chemother. 48, 739-746 (2004). 9. Haltli, B. et al. Investigating β-Hydroxyenduracididine Formation in the Biosynthesis of the Mannopeptimycins. Chem. Biol. 12, 1163-1168 (2005). 10. Khare, M. & Keady, D. Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection. Expert Opin Pharmacother 4, 165-177 (2003). 11. Magarvey, N.A., Haltli, B., He, M., Greenstein, M. & Hucul, J.A. Biosynthetic Pathway for Mannopeptimycins, Lipoglycopeptide Antibiotics Active against Drug-Resistant Gram-Positive Pathogens. Antimicrob. Agents Chemother. 50, 2167-2177 (2006). 12. Fontecave, M., Atta, M. & Mulliez, E. S-adenosylmethionine: nothing goes to waste. Trends Biochem. Sci. 29, 243-249 (2004). 13. Schubert, H.L., Blumenthal, R.M. & Cheng, X. Many paths to methyltransfer: a chronicle of convergence. Trends Biochem. Sci. 28, 329-335 (2003). 14. Martin, J.L. & McMillan, F.M. SAM (dependent) I AM: the S-adenosylmethionine-dependent methyltransferase fold. Curr. Opin. Struct. Biol. 12, 783-793 (2002). 15. Thibodeaux, C.J., Melancon, C.E. & Liu, H.-w. Natural-Product Sugar Biosynthesis and Enzymatic Glycodiversification. Angew. Chem. Int. Ed. 47, 9814-9859 (2008). 16. Thibodeaux, C.J., Melancon, C.E. & Liu, H.-w. Unusual sugar biosynthesis and natural product glycodiversification. Nature 446, 1008-1016 (2007). 17. Zubieta, C., He, X.-Z., Dixon, R.A. & Noel, J.P. Structures of two natural product methyltransferases reveal the basis for substrate specificity in plant O-methyltransferases. Nat Struct Mol Biol 8, 271-279 (2001). 18. Liu, Y.C. et al. Interception of teicoplanin oxidation intermediates yields new antimicrobial scaffolds. Nat. Chem. Biol. 7, 304-309 (2011). 19. Chan, H.-C. et al. Regioselective deacetylation based on teicoplanin-complexed Orf2* crystal structures. Molecular BioSystems 7, 1224-1231 (2011). 20. Li, T.-L., Liu, Y.-C. & Lyu, S.-Y. Combining biocatalysis and chemoselective chemistries for glycopeptide antibiotics modification. Curr. Opin. Chem. Biol. 16, 170-178 (2012). 21. Houge-Frydrych, C.S., Gilpin, M.L., Skett, P.W. & Tyler, J.W. SB-203207 and SB-203208, two novel isoleucyl tRNA synthetase inhibitors from a Streptomyces sp. II. Structure determination. J. Antibiot. (Tokyo). 53, 364-372 (2000). 22. Huang, Y.-T. et al. In vitro Characterization of Enzymes Involved in the Synthesis of Nonproteinogenic Residue (2S,3S)-β-Methylphenylalanine in Glycopeptide Antibiotic Mannopeptimycin. ChemBioChem 10, 2480-2487 (2009). 23. Lin, H. S-Adenosylmethionine-dependent alkylation reactions: When are radical reactions used? Bioorg. Chem. 39, 161-170 (2011). 24. Akey, D.L. et al. A New Structural Form in the SAM/Metal-Dependent O‑Methyltransferase Family: MycE from the Mycinamicin Biosynthetic Pathway. J. Mol. Biol. 413, 438-450 (2011). 25. Gomez Garcia, I. et al. The Crystal Structure of the Novobiocin Biosynthetic Enzyme NovP: The First Representative Structure for the TylF O-Methyltransferase Superfamily. J. Mol. Biol. 395, 390-407 (2010). 26. Kopycki, J.G. et al. Biochemical and Structural Analysis of Substrate Promiscuity in Plant Mg2+-Dependent O-Methyltransferases. J. Mol. Biol. 378, 154-164 (2008). 27. Duschene, K.S., Veneziano, S.E., Silver, S.C. & Broderick, J.B. Control of radical chemistry in the AdoMet radical enzymes. Curr. Opin. Chem. Biol. 13, 74-83 (2009). 28. Frey, P.A., Hegeman, A.D. & Ruzicka, F.J. The Radical SAM Superfamily. Crit. Rev. Biochem. Mol. Biol. 43, 63-88 (2008). 29. Otwinowski, Z. & Minor, W. [20] Processing of X-ray diffraction data collected in oscillation mode, in Methods in Enzymology, Vol. Volume 276. (ed. Charles W. Carter, Jr.) 307-326 (Academic Press, 1997). 30. Kantardjieff, K.A. & Rupp, B. Matthews coefficient probabilities: Improved estimates for unit cell contents of proteins, DNA, and protein–nucleic acid complex crystals. Protein Sci. 12, 1865-1871 (2003). 31. Ness, S.R., de Graaff, R.A.G., Abrahams, J.P. & Pannu, N.S. Crank: New methods for automated macromolecular crystal structure solution. Structure 12, 1753-1761 (2004). 32. De Graaff, R.A.G., Hilge, M., Van Der Plas, J.L. & Abrahams, J.P. Matrix methods for solving protein substructures of chlorine and sulfur from anomalous data. Acta Crystallographica Section D 57, 1857-1862 (2001). 33. Pannu, N.S. & Read, R.J. The application of multivariate statistical techniques improves single-wavelength anomalous diffraction phasing. Acta Crystallographica Section D 60, 22-27 (2004). 34. Abrahams, J.P. & Leslie, A.G.W. Methods used in the structure determination of bovine mitochondrial F1 ATPase. Acta Crystallographica Section D 52, 30-42 (1996). 35. Cowtan, K. Fitting molecular fragments into electron density. Acta Crystallographica Section D 64, 83-89 (2008). 36. Cowtan, K. The Buccaneer software for automated model building. 1. Tracing protein chains. Acta Crystallographica Section D 62, 1002-1011 (2006). 37. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallographica Section D 66, 486-501 (2010). 38. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallographica Section D 60, 2126-2132 (2004). 39. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of Macromolecular Structures by the Maximum-Likelihood Method. Acta Crystallographica Section D 53, 240-255 (1997). 40. Schuck, P. Size-Distribution Analysis of Macromolecules by Sedimentation Velocity Ultracentrifugation and Lamm Equation Modeling. Biophys. J. 78, 1606-1619 (2000). 41. Ravel, B. & Newville, M. ATHENA, ARTEMIS, HEPHAESTUS: data analysis for X-ray absorption spectroscopy using IFEFFIT. Journal of Synchrotron Radiation 12, 537-541 (2005). 42. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007). 43. Dunwell, J.M., Purvis, A. & Khuri, S. Cupins: the most functionally diverse protein superfamily? Phytochemistry 65, 7-17 (2004). 44. Dunwell, J.M. Cupins: a new superfamily of functionally diverse proteins that include germins and plant storage proteins. Biotechnol. Genet. Eng. Rev. 15, 1-32 (1998). 45. Conrad, J.A. & Moran, G.R. The interaction of hydroxymandelate synthase with the 4-hydroxyphenylpyruvate dioxygenase inhibitor: NTBC. Inorg. Chim. Acta 361, 1197-1201 (2008). 46. Brownlee, J., He, P., Moran, G.R. & Harrison, D.H.T. Two Roads Diverged: The Structure of Hydroxymandelate Synthase from Amycolatopsis orientalis in Complex with 4-Hydroxymandelate†,‡. Biochemistry (Mosc). 47, 2002-2013 (2008). 47. Purpero, V. & Moran, G. The diverse and pervasive chemistries of the α-keto acid dependent enzymes. J Biol Inorg Chem 12, 587-601 (2007). 48. Moran, G.R. 4-Hydroxyphenylpyruvate dioxygenase. Arch. Biochem. Biophys. 433, 117-128 (2005). 49. Singh, S. et al. Structure and Mechanism of the Rebeccamycin Sugar 4′-O-Methyltransferase RebM. J. Biol. Chem. 283, 22628-22636 (2008). 50. Vidgren, J., Svensson, L.A. & Liljas, A. Crystal structure of catechol O-methyltransferase. Nature 368, 354-358 (1994). 51. Mannisto, P.T. & Kaakkola, S. Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors. Pharmacol. Rev. 51, 593-628 (1999). 52. Schluckebier, G., O'Gara, M., Saenger, W. & Cheng, X. Universal Catalytic Domain Structure of AdoMet-dependent Methyltransferases. J. Mol. Biol. 247, 16-20 (1995). 53. Costas, M., Mehn, M.P., Jensen, M.P. & Que, L. Dioxygen Activation at Mononuclear Nonheme Iron Active Sites: Enzymes, Models, and Intermediates. Chem. Rev. 104, 939-986 (2004). 54. Solomon, E.I. et al. Geometric and Electronic Structure/Function Correlations in Non-Heme Iron Enzymes. Chem. Rev. 100, 235-350 (2000). 55. Decker, A. & Solomon, E.I. Dioxygen activation by copper, heme and non-heme iron enzymes: comparison of electronic structures and reactivities. Curr. Opin. Chem. Biol. 9, 152-163 (2005). 56. Gerlt, J.A., Kreevoy, M.M., Cleland, W.W. & Frey, P.A. Understanding enzymic catalysis: the importance of short, strong hydrogen bonds. Chem. Biol. 4, 259-267 (1997). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/6120 | - |
dc.description.abstract | 細菌抗藥性問題日益嚴重,使得發展新型抗生素更加困難,藉由改變抗生素生合成路徑而改變抗生素結構,提供我們一個可能克服細菌抗藥性問題的機會。Dbv29為參與抗生素A40926生合成之六碳糖氧化酶,利用X光蛋白質結晶學與生物化學的方法,我們解析出Dbv29的蛋白質結構以及催化作用機制,並且發現一對酪胺酸活性基團在輔酶蛋白共價結合、酵素活性及維持蛋白質結構上扮演非常重要的角色。更特別的是,受質在Dbv29與teicoplanin複合體蛋白質結構中以反應中間產物呈現,使我們得以進一步利用Dbv29合成各種不同化學結構的衍生物。在抑菌測試中,部分的衍生物對於具有抗藥性的腸球菌(VRE)比抗生素vancomycin與teicoplanin表現出更好的抑菌效果。因此利用這嶄新的方法我們可以發展出更多不同型態的抗生素衍生物來解決細菌抗藥性問題。S-腺苷甲硫氨酸(SAM)必需之甲基轉移酶(methyltransferases)為最具多樣性及重要生物活性功能的酵素之一。(2S,3S)-β-甲基苯丙氨酸(βMePhe)為非蛋白氨基酸,是組成醣胜肽抗生素mannopeptimycin六環胜肽中的部分化學分子。我們先前的研究發現,mannopeptimycin生合成mppJ基因利用S-腺苷甲硫氨酸(SAM)將苯丙酮酸(Ppy)上苯甲基的碳甲基化而產生β-甲基苯丙酮酸(β-MePpy),雖然其苯甲基的碳具有部分酸性,但是並不表示這碳原子一定會進行親和性取代反應。特別的是純化之MppJ蛋白質呈現藍綠色,意指MppJ有金屬離子參與催化反應,但不同於目前已知鎂(Mg2+)或鈣(Ca2+)離子必需之甲基轉移酶以及自由基反應機制之甲基轉移酶。我們利用X光蛋白質結晶學與生物化學的方法,解析出MppJ的蛋白質結構以及催化作用機制,藉由分析蛋白質與受質(substrates)及產物(products)複合體蛋白結構,我們發現MppJ為目前唯一鐵離子(Fe3+)及S-腺苷甲硫氨酸(SAM)必需之甲基轉移酶,並且知道MppJ如何在碳原子上發生甲基化反應的催化機制。多個複合體蛋白結構使我們了解MppJ利用鐵離子與α酮基酸(α-ketoacid)結合配位與活化,並且發展出兩個水分子裝置來控制酵素專一性進行碳上甲基化反應。如此發現使我們更進一步將甲基轉移酶改變成結構與功能不相關的新酵素。我們藉由改變金屬離子的配位化學,使得原本酵素變成具有水合酶及甲基轉移酶的雙重功能,進而產生具有立體特異性的新化學分子。 | zh_TW |
dc.description.abstract | In the search for new efficacious antibiotics, biosynthetic engineering offers attractive opportunities to introduce minor alterations to antibiotic structures that may overcome resistance. Dbv29, a flavin-containing oxidase, catalyzes the four-electron oxidation of a vancomycin-like glycopeptide to yield A40926. Structural and biochemical examination of Dbv29 now provides insights into residues that govern flavinylation and activity, protein conformation and reaction mechanism. In particular, the serendipitous discovery of a reaction intermediate in the crystal structure led us to identify an unexpected opportunity to intercept the normal enzyme mechanism at two different points to create new teicoplanin analogs. Using this method, we synthesized families of antibiotic analogs with amidated and aminated lipid chains, some of which showed marked potency and efficacy against multidrug resistant pathogens. This method offers a new strategy for the development of chemical diversity to combat antibacterial resistance.
The S-adenosyl-L-methionine (SAM)-dependent methyltransferases (MTs) represent one of the most diverse and biologically important classes of enzymes. (2S,3S)-β-methylphenylalanine, a nonproteinogenic amino acid, is a building unit in glycopeptide antibiotic mannopeptimycin. The mppJ gene product in the mannopeptimycin biosynthetic gene cluster was determined to be the committed MT to methylate the benzylic carbon of phenylpyruvate (Ppy) into β-MePpy. The benzylic carbon of Ppy has some extent of acidity, but its acting as an operational nucleophile was not concluded. The purified MppJ displays a turquoise color implicating involvement of a metal ion. The solved crystal structures revealed MppJ the first ferric ion/SAM-dependent MT. Additional four structures in binary and ternary complexes illustrated the molecular mechanism for the metal ion dependent MT reaction. MppJ has evolved a non-heme iron center to bind, orientate and activate the α-ketoacid substrate and meanwhile developed a sandwiched bi-water device to avoid formation of the unwanted reactive oxo-Fe(IV) species during the C-MT reaction. This unprecedented discovery further prompted us to convert the MT into a structurally/functionally unrelated new enzyme. Through stepwise-protein engineering and manipulation of coordination chemistry MTs were engineered to perform both non-heme iron dependent hydration and methyltransferation reactions for stereo-specific new compounds. The process was validated by five crystal structures. | en |
dc.description.provenance | Made available in DSpace on 2021-05-16T16:21:20Z (GMT). No. of bitstreams: 1 ntu-102-D98b46019-1.pdf: 20088593 bytes, checksum: 6807158870a44084e2fb361a64bac741 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | Table of Contents
Verification letter from the oral examination i Acknowledgement ii Section 1. Interception of teicoplanin oxidation intermediates yields new antimicrobial scaffolds iii Chinese abstract iv Abstract v Table of Contents vi List of Figures ix List of Tables x 1. Introduction 1 1.1 Emerging of resistant pathogens 1 1.2 Glycopeptide antibiotics 1 1.3 Modifications of glycopeptide antibiotics by 3 1.4 Dbv29 3 2. Materials and Methods 6 2.1 Gene cloning and protein purification 6 2.2 Crystallization and data collection 6 2.3 Structure determination and refinement 7 2.4 Enzymatic activity 8 2.5 Mutagenesis 8 2.6 Circular dichroism spectroscopy 8 2.7 Analytical ultracentrifuge analysis 9 2.8 Synthetic conditions for new analogs 9 2.9 Compound characterization 10 2.10 In vivo study 12 3. Results 13 3.1 Dbv29 is a FAD-containing dimer 13 3.2 Contributions to cofactor- and substrate-binding sites 13 3.3 A diol intermediate leads to catalytic redirection 15 3.4 Analogs provide alternate antimicrobial protection 17 3.5 Dbv29 has a dynamic quaternary structure 18 4. Discussion 20 References 48 Section 2. Structure and mechanism of non-heme iron-SAM dependent methyltransferase and its engineering to hydratase xi Chinese abstract xii Abstract xiii List of Figures xiv List of Tables xv 1. Introduction 52 1.1 Mannopeptimycin 52 1.2 Methyltransferases and methylation 54 1.3 MppJ 55 2. Materials and Methods 57 2.1 Gene cloning 57 2.2 Protein expression and purification 57 2.3 Crystallization and data collection58 2.4 Structure determination and refinement 58 2.5 Enzymatic reaction 59 2.6 Site-directed mutagenesis 59 2.7 Analytical ultracentrifugation analysis 60 2.8 Isothermal titration calorimetry analysis 60 2.9 X-ray absorption spectroscopy 60 2.10 Electron paramagnetic resonance spectroscopy 61 2.11 Chiral HPLC analysis 61 3. Results 62 3.1 Protein crystallization and structure determination 62 3.2 Overview of the structure 63 3.3 Conformational change and SAM/SAH-binding 64 3.4 Ppy-binding site and coordination chemistry 65 3.5 Reaction mechanism 66 3.6 No non-heme oxygnease activity 68 3.7 Stereochemistry 70 3.7.1 Methylation 70 3.7.2 Post-translational modification 71 3.7.3 Methoxylation 72 4. Discussion 73 References 93 Appendix xvi List of Figures Figure 1. Structures of relevant glycopeptide antibiotics. 21 Figure 2. The structure of Dbv29 and its enzymatic mechanism. 22 Figure 3. Intermediate trapping strategies to probe the catalytic mechanism. 23 Figure 4. Variations in acyl chain length regulate the resultant glycopeptide analogue. 24 Figure 5. Mice infection test for analog 25 in blood bacterial clearance. 25 Figure 6. Structural analysis of dimeric and monomeric Dbv29. 26 Figure 7. Analytical ultracentrifugation (AUC) analyses for Dbv29 and mutants. 28 Figure 8. Circular dichroism (CD) analyses for Dbv29 and mutants. 30 Figure 9. CD analysis of protein stability. 31 Figure 10. MS and MSMS spectra of the benzylamine-Tei aminated analog (25). 32 Figure 11. NMR information for de-r4-Tei. NMR spectra include 1H, 13C, HSQC,HMBC, and COSY. 35 Figure 12. NMR information for analog 25. NMR spectra include 1H, 13C, HSQC,HMBC, and COSY. 38 Figure 13. HRMS data for representative compounds. 39 List of Tables Table 1. MICs of vancomycin, teicoplanin and analogs against tested strains. 40 Table 2. Data collection and refinement statistics for Dbv29 structures. 41 Table 3. Relative enzymatic activities of Dbv29 mutants. 42 Table 4. Product yields of oxidized, aminated or amidated teicoplanin analogs synthesized by Dbv29. 44 Table 5. NMR assignments for compound 25 as determined from spectra shown in Figures 11 and 12. 47 List of Figures Figure 1. Chemical structures of mannopeptimycins. 74 Figure 2. Multiple sequence alignments for MppJ and homologues. 75 Figure 3. Crystal structures of MppJ complexed with substrates or products. 77 Figure 4. Gel filtration and analytical ultracentrifugation analyses of MppJ. 78 Figure 5. Schematic topology of MppJ. 79 Figure 6. Conformational change and SAM/SAH-binding. 80 Figure 7. Ppy binding site and metal (Fe3+) coordination in MppJ structure. 81 Figure 8. Metal ion determination by X-ray absorption spectroscopy (XAS) and electron paramagnetic resonance (EPR). 82 Figure 9. Active site structure of MppJ and proposed catalytic mechanism. 83 Figure 10. Isothermal titration calorimetry (ITC) analyses of MppJ. 84 Figure 11. HPLC traces of enzymatic reactions for MppJ WT, D244L, and D244E mutants. 85 Figure 12. Active site structures of MppJ D244E and D244L mutants. 86 Figure 13. Chiral HPLC analyses of MppJ. 87 Figure 14. Ppy/4HPpy are covalently linked to Cys319. 88 Figure 15. Active site structures of MppJ mutants and proposed mechanism for new compound. 89 List of Tables Table 1. Data collection, phasing and refinement statistics for MppJ structures. 90 Table 2. Relative enzymatic activities (MT), enzyme colors and proposed residue functions. 92 | |
dc.language.iso | en | |
dc.title | 醣胜肽抗生素生合成酵素蛋白晶體結構及反應機制為基礎的新化學結構生物活性分子設計 | zh_TW |
dc.title | Structure- and mechanism-based enzyme design for biologically active new chemical entities on glycopeptide antibiotics | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 蔡明道(Ming-Daw Tsai) | |
dc.contributor.oralexamcommittee | 梁博煌(Po-Huang Liang),馬徹(Che Ma),林世昌(Su-Chang Lin) | |
dc.subject.keyword | 醣胜?抗生素,teicoplanin衍生物,氧化還原?還原胺化,抗萬古黴素腸球菌(VRE),mannopeptimycin,非蛋白氨基酸,甲基轉移?,S-腺?甲硫氨酸(SAM),苯丙酮酸(Ppy), | zh_TW |
dc.subject.keyword | glycopeptide antibiotics,teicoplanin analogs,oxidoreductase,reductive amination,vancomycin-resistant Enterococcus (VRE),mannopeptimycin,nonproteinogenic amino acid,methyltransferase,S-adenosyl-L-methionine (SAM),phenylpyruvic acid (Ppy), | en |
dc.relation.page | 104 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2013-07-30 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科學研究所 | zh_TW |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf | 19.62 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。